Published in Arch Neurol on June 01, 2012
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci (2013) 2.26
Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol (2014) 2.13
Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol (2013) 2.03
Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J Neurosci (2013) 2.01
The role of clusterin in amyloid-β-associated neurodegeneration. JAMA Neurol (2014) 1.67
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol (2012) 1.57
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol (2013) 1.31
What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol (2014) 1.29
Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol (2013) 1.29
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain (2016) 1.25
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin (2013) 1.02
Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. J Neurosci (2014) 1.00
The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement (2013) 0.98
Early etiology of Alzheimer's disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol (2015) 0.97
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol (2015) 0.94
Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol (2014) 0.93
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology (2013) 0.92
Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry (2015) 0.92
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiol Aging (2014) 0.88
Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement (2014) 0.87
Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data. Alzheimers Dement (2014) 0.87
Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag (2013) 0.86
The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev (2014) 0.86
Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. J Int Neuropsychol Soc (2014) 0.85
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. Mol Psychiatry (2016) 0.81
Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? Cereb Cortex (2013) 0.81
Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. J Int Neuropsychol Soc (2015) 0.80
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med (2012) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
An expanded role for neuroimaging in the evaluation of memory impairment. AJNR Am J Neuroradiol (2013) 0.78
Evaluating Alzheimer's Disease Progression by Modeling Crosstalk Network Disruption. Front Neurosci (2016) 0.78
MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. Sci Rep (2016) 0.77
Tau facilitates Aβ-induced loss of mitochondrial membrane potential independent of cytosolic calcium fluxes in mouse cortical neurons. Neurosci Lett (2015) 0.76
The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease. Acta Neuropathol Commun (2016) 0.76
Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer's disease. Transl Neurodegener (2016) 0.75
A new coumarin derivative, IMM-H004, attenuates okadaic acid-induced spatial memory impairment in rats. Acta Pharmacol Sin (2016) 0.75
Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clin Neuropsychol (2016) 0.75
Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. Neuroimage Clin (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol (2011) 1.83
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord (2005) 1.52
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron (2002) 33.99
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Automatically parcellating the human cerebral cortex. Cereb Cortex (2004) 18.32
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci (2009) 12.05
Sequence-independent segmentation of magnetic resonance images. Neuroimage (2004) 11.36
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Thinning of the cerebral cortex in aging. Cereb Cortex (2004) 8.31
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol (2004) 4.89
Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry (2003) 4.84
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Dorsal anterior cingulate cortex: a role in reward-based decision making. Proc Natl Acad Sci U S A (2001) 4.20
Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci (2006) 4.14
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Effects of age on volumes of cortex, white matter and subcortical structures. Neurobiol Aging (2005) 3.63
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA (2010) 3.58
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy. Neuroimage (2004) 3.48
Depth-resolved optical imaging and microscopy of vascular compartment dynamics during somatosensory stimulation. Neuroimage (2007) 3.07
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (2010) 2.88
High consistency of regional cortical thinning in aging across multiple samples. Cereb Cortex (2009) 2.88
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Spatial extent of oxygen metabolism and hemodynamic changes during functional activation of the rat somatosensory cortex. Neuroimage (2005) 2.79
Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygenation level-dependent signal. J Neurosci (2007) 2.76
Simultaneous imaging of total cerebral hemoglobin concentration, oxygenation, and blood flow during functional activation. Opt Lett (2003) 2.70
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet (2013) 2.68
Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A (2008) 2.65
Coupling of total hemoglobin concentration, oxygenation, and neural activity in rat somatosensory cortex. Neuron (2003) 2.64
On-line automatic slice positioning for brain MR imaging. Neuroimage (2005) 2.62
Life-span changes of the human brain white matter: diffusion tensor imaging (DTI) and volumetry. Cereb Cortex (2009) 2.62
One-year brain atrophy evident in healthy aging. J Neurosci (2009) 2.61
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA (2017) 2.58
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci (2013) 2.51
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage (2011) 2.50
Real-time rigid body motion correction and shimming using cloverleaf navigators. Magn Reson Med (2006) 2.50
Spatiotemporal dynamics of modality-specific and supramodal word processing. Neuron (2003) 2.42
Neuroanatomical assessment of biological maturity. Curr Biol (2012) 2.40
Common genetic variants influence human subcortical brain structures. Nature (2015) 2.40
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Human posterior auditory cortex gates novel sounds to consciousness. Proc Natl Acad Sci U S A (2004) 2.33
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Hierarchical genetic organization of human cortical surface area. Science (2012) 2.28
Efficient correction of inhomogeneous static magnetic field-induced distortion in Echo Planar Imaging. Neuroimage (2009) 2.28
Coupling of the cortical hemodynamic response to cortical and thalamic neuronal activity. Proc Natl Acad Sci U S A (2005) 2.28
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Intracranial EEG reveals a time- and frequency-specific role for the right inferior frontal gyrus and primary motor cortex in stopping initiated responses. J Neurosci (2009) 2.25
Towards effective and rewarding data sharing. Neuroinformatics (2003) 2.24
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Cortical depth-specific microvascular dilation underlies laminar differences in blood oxygenation level-dependent functional MRI signal. Proc Natl Acad Sci U S A (2010) 2.22
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann Neurol (2015) 2.16
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Monte Carlo simulation studies of EEG and MEG localization accuracy. Hum Brain Mapp (2002) 2.12
Modifying resilience mechanisms in at-risk individuals: a controlled study of mindfulness training in Marines preparing for deployment. Am J Psychiatry (2014) 2.12
Association between older age and more successful aging: critical role of resilience and depression. Am J Psychiatry (2013) 2.11
Consistent neuroanatomical age-related volume differences across multiple samples. Neurobiol Aging (2009) 2.08
All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genet (2013) 2.08
Current-source density estimation based on inversion of electrostatic forward solution: effects of finite extent of neuronal activity and conductivity discontinuities. J Neurosci Methods (2006) 2.06
Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla. Neuroimage (2002) 2.05